Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AIM ImmunoTech Inc.AIM · Entity 8131 | Director · CEO & President | September 17, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AIM ImmunoTech Inc.
Report date September 17, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,822 |
Reported balance
After 2026-09-17 transaction · row 1
1 source rowRow 1 · 2026-09-17 · Purchase · Acquired 24,000 · Balance 126,822 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2020 Filed Aug 14, 2020 19:32 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantOptions · Derivative | 300,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001450324-20-000004 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-08-12 Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 15:47 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 14,741 | $0.53 | $7,812.73 |
DisclosureSEC source: 0001450324-20-000001 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec.Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,990 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 14:25 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 17,960 | $0.44 | $7,812.60 |
DisclosureSEC source: 0001450324-19-000028 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec.Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,249 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| November 29, 2019 Filed Dec 2, 2019 16:48 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 19,531 | $0.40 | $7,812.40 |
DisclosureSEC source: 0001450324-19-000023 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec.Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,289 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 19:30 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 16,622 | $0.47 | $7,812.34 |
DisclosureSEC source: 0001450324-19-000018 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec.Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,758 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| October 31, 2019 Filed Oct 31, 2019 15:36 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 15,625 | $0.50 | $7,812.50 |
DisclosureSEC source: 0001450324-19-000017 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,136 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 20:32 UTC | AIM ImmunoTech Inc. AIM · Entity 8131 | GrantCommon Stock | 13,470 | $0.58 | $7,812.60 |
DisclosureSEC source: 0001450324-19-000013 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,511 F1 · kind: Common Stock Award. Vests in six months, provided continuous employment. Read SEC document |
| June 27, 2019 Filed Jun 27, 2019 19:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 2,632 | $4.37 | $11,501.84 |
DisclosureSEC source: 0001450324-19-000012 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,041 Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 15:11 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 29,404 | $4.03 | $118,498.12 |
DisclosureSEC source: 0001450324-19-000011 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,393,611 Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 16:17 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 29,404 | $4.03 | $118,498.12 |
DisclosureSEC source: 0001702626-19-000006 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,409 F1 · balance_after: The amount of securities previously owned is being adjusted due to the 44 to 1 reverse stock split which occurred on June 11, 2019. Read SEC document |
| May 08, 2019 Filed Jun 17, 2019 17:23 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 227,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000003 · primary_doc.xml · nonDerivative · entry 2 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,364,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Rights offering warrants using the cashless conversion feature , were converted into .70 number of shares. Read SEC document |
| March 19, 2019 Filed Mar 19, 2019 20:01 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 13,400 | $0.18 | $2,351.70 |
DisclosureSEC source: 0001450324-19-000009 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811,707 Read SEC document |
| March 18, 2019 Filed Jun 17, 2019 17:23 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | ConversionCommon Stock | 325,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001613377-19-000003 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,136,707 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share has a stated value of $1,000 and was converted into 5,000 shares of Series B Common Stock for each of the 65 shares issued. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 20:29 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSubr Rights(to buy) · Derivative | 65 | $1,000.00 Strike: $1,000.00 | $65,000.00 |
DisclosureSEC source: 0001450324-19-000008 · primary_doc.xml · derivative · entry 3 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Pref Stk/Warrants · Not disclosed shares Expires 2019-03-05 F1 · derivative.underlying: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F2 · derivative.underlying: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · derivative.underlying_shares: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 share of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 20:29 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherWarrants | 325,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001450324-19-000008 · primary_doc.xml · nonDerivative · entry 2 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 F2 · security: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · shares: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F2 · price: Each warrant is exercisable for one share of common stock at an exercise price of $0.20 per share and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 share of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| February 27, 2019 Filed Mar 12, 2019 20:29 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherSeries B Convertible Preferred Stock | 65 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001450324-19-000008 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65 F1 · security: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · shares: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F1 · price: Each share has a stated value of $1,000 and is convertible into 5,000 shares of common stock and was issued as part of a subscription right issued in a rights offering. F3 · price: Represents $1,000 per unit purchased in the rights offering, each unit consisting of 1 share of Series B Preferred Stock and 5,000 warrants. Read SEC document |
| January 28, 2019 Filed Jan 30, 2019 15:20 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 426,136 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001450324-19-000001 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 426,136 Underlying: Common Stock · 426,136 shares Expires 2029-01-28 F1 · security: This option is being issued to senior management for a voluntary 50% deferral in salary. Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 6,000 | $0.20 | $1,176.00 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 8 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798,307 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 334 | $0.19 | $64.96 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 7 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 792,307 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 300 | $0.19 | $58.32 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 6 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,973 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 50 | $0.19 | $9.69 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 5 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,673 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 2,400 | $0.19 | $463.20 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 4 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,623 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 9,557 | $0.19 | $1,815.83 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 3 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,223 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 5 | $0.19 | $0.95 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 2 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,666 Read SEC document |
| November 30, 2018 Filed Dec 3, 2018 16:32 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 1,354 | $0.19 | $256.04 |
DisclosureSEC source: 0001450324-18-000008 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 779,661 Read SEC document |
| November 27, 2018 Filed Nov 29, 2018 15:34 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001613377-18-000036 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 778,307 F1 · kind: The Board of Directors awarded 2,500 shares of Company common stock to each employee, executive, and board member as a holiday bonus to be issued after January 2, 2019. Read SEC document |
| November 14, 2018 Filed Nov 16, 2018 16:22 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 1,000 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000029 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-11-14 F1 · security: This option has been awarded by the Board of Directors. Read SEC document |
| October 26, 2018 Filed Oct 29, 2018 13:14 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 3,500 | $0.20 | $710.50 |
DisclosureSEC source: 0001450324-18-000007 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,807 Read SEC document |
| October 25, 2018 Filed Oct 25, 2018 13:22 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 100,000 | $0.20 | $20,000.00 |
DisclosureSEC source: 0001450324-18-000006 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 772,307 Read SEC document |
| October 17, 2018 Filed Oct 19, 2018 16:31 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 284,091 | $0.00 Strike: $0.22 | $0.00 |
DisclosureSEC source: 0001613377-18-000024 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,091 Underlying: Common Stock · 284,091 shares Expires 2028-10-17 F1 · security: This option is being issued to senior management in exchange for a voluntary 50% deferral in salary. Read SEC document |
| July 27, 2018 Filed Jul 27, 2018 13:31 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 34,483 | $0.29 | $10,000.07 |
DisclosureSEC source: 0001450324-18-000005 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 672,306 Read SEC document |
| July 23, 2018 Filed Jul 23, 2018 14:49 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 112,904 | $0.31 | $35,000.24 |
DisclosureSEC source: 0001613377-18-000020 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,823 Read SEC document |
| July 18, 2018 Filed Jul 19, 2018 18:41 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 161,290 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001450324-18-000004 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,290 Underlying: Common Stock · 161,290 shares Expires 2028-07-18 F1 · security: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| May 16, 2018 Filed May 18, 2018 15:13 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherOptions to buy Common Stock · Derivative | 300,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001613377-18-000009 · primary_doc.xml · derivative · entry 2 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,833 Underlying: Common Stock · 300,000 shares Expires 2028-05-16 F2 · security: Stock options issued per the employment agreement. Read SEC document |
| May 16, 2018 Filed May 18, 2018 15:13 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 250,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001613377-18-000009 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2028-05-16 F1 · security: This option is being issued to senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| April 27, 2018 Filed Apr 30, 2018 10:22 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 32,000 | $0.32 | $10,240.00 |
DisclosureSEC source: 0001450324-18-000002 · primary_doc.xml · nonDerivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 524,919 Read SEC document |
| April 12, 2018 Filed Apr 19, 2018 19:01 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 125,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001465652-18-000006 · primary_doc.xml · derivative · entry 1 EQUELS THOMAS K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-04-12 F1 · security: This option is being awarded by the Board of Directors. Read SEC document |
| February 13, 2018 Filed Mar 1, 2018 20:12 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 371,622 | $0.00 Strike: $0.37 | $0.00 |
DisclosureSEC source: 0001191434-18-000002 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · Exec. Vice Chairman/CEO/Pres. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,622 Underlying: Common Stock · 371,622 shares Expires 2028-02-13 F1 · security: This option is being issued by senior management in exchange for a voluntary 40% deferral in salary. Read SEC document |
| August 31, 2017 Filed Sep 1, 2017 18:15 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 24,463 | $0.26 Strike: $0.36 | $6,360.38 |
DisclosureSEC source: 0001613377-17-000044 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,463 Underlying: Common Stock · 24,463 shares Expires 2027-08-31 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| August 15, 2017 Filed Aug 16, 2017 16:40 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 21,336 | $0.29 Strike: $0.41 | $6,187.44 |
DisclosureSEC source: 0001613377-17-000035 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,336 Underlying: Common Stock · 21,336 shares Expires 2027-08-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:14 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 20,786 | $0.30 Strike: $0.42 | $6,235.80 |
DisclosureSEC source: 0001613377-17-000030 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,786 Underlying: Common Stock · 20,786 shares Expires 2027-07-31 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| July 15, 2017 Filed Jul 17, 2017 20:24 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 18,124 | $0.34 Strike: $0.48 | $6,162.16 |
DisclosureSEC source: 0001613377-17-000023 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,124 Underlying: Common Stock · 18,124 shares Expires 2027-07-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 17:05 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,214 | $0.44 Strike: $0.49 | $6,254.16 |
DisclosureSEC source: 0001613377-17-000017 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,214 Underlying: Common Stock · 14,214 shares Expires 2027-06-30 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 20:51 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,293 | $0.44 Strike: $0.54 | $6,288.92 |
DisclosureSEC source: 0001613377-17-000010 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,293 Underlying: Common Stock · 14,293 shares Expires 2027-06-15 F1 · security: This option is being issued in exchange for a voluntary 20% deduction in salary. F1 · price: This option is being issued in exchange for a voluntary 20% deduction in salary. Read SEC document |
| June 15, 2017 Filed Jun 29, 2017 17:49 UTC Amendment | AIM ImmunoTech Inc. HEB · Entity 8131 | GrantOptions to buy Common Stock · Derivative | 14,212 | $0.44 Strike: $0.49 | $6,253.28 |
DisclosureSEC source: 0001613377-17-000014 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,212 Underlying: Common Stock · 14,212 shares Expires 2027-06-15 F1 · security: Amendment due to salary reduction as explained in the 8-K filed on June 22, 2017. F1 · price: Amendment due to salary reduction as explained in the 8-K filed on June 22, 2017. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 15:55 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | OtherOptions to buy Common Stock · Derivative | 300,000 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001450324-17-000003 · primary_doc.xml · derivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO / President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,833 Underlying: Common Stock · 300,000 shares Expires 2027-06-08 F1 · kind: Stock Options issued per the employment agreement. Read SEC document |
| April 27, 2017 Filed Apr 27, 2017 13:27 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 72,464 | $0.69 | $50,000.16 |
DisclosureSEC source: 0001450324-17-000002 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,919 Read SEC document |
| April 11, 2017 Filed Apr 11, 2017 13:54 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 200,000 | $0.50 | $100,000.00 |
DisclosureSEC source: 0001450324-17-000001 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,455 Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 17:31 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 68,493 | $0.73 | $49,999.89 |
DisclosureSEC source: 0001450324-16-000016 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO, President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,455 Read SEC document |
| November 01, 2016 Filed Nov 1, 2016 17:27 UTC | AIM ImmunoTech Inc. HEB · Entity 8131 | PurchaseCommon Stock | 10,000 | $1.00 | $10,000.00 |
DisclosureSEC source: 0001450324-16-000015 · primary_doc.xml · nonDerivative · entry 1 Equels Thomas K. · CIK 0001450324 · Director · CEO,President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,962 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.